{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:38:04Z","timestamp":1789983484270,"version":"4.0.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K23 AG050260"],"award-info":[{"award-number":["K23 AG050260"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG054366"],"award-info":[{"award-number":["R01 AG054366"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U10 AA013566"],"award-info":[{"award-number":["U10 AA013566"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U24 AA020794"],"award-info":[{"award-number":["U24 AA020794"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01 AA020790"],"award-info":[{"award-number":["U01 AA020790"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 068636"],"award-info":[{"award-number":["AI 068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 HL125032"],"award-info":[{"award-number":["R01 HL125032"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,30]]},"DOI":"10.1093\/infdis\/jix586","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T20:12:31Z","timestamp":1510603951000},"page":"521-528","source":"Crossref","is-referenced-by-count":22,"title":["Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?"],"prefix":"10.1093","volume":"217","author":[{"given":"Amy C","family":"Justice","sequence":"first","affiliation":[{"name":"VA Connecticut Healthcare System West Haven, Yale University, New Haven, Connecticut"},{"name":"School of Medicine, Yale University, New Haven, Connecticut"},{"name":"School of Public Health, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine M","family":"Erlandson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"},{"name":"Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"Hunt","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, Department of Medicine, University of California\u2013San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Landay","sequence":"additional","affiliation":[{"name":"Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Miotti","sequence":"additional","affiliation":[{"name":"Office of AIDS Research, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell P","family":"Tracy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Colchester"},{"name":"Department of Biochemistry, University of Vermont Larner College of Medicine, Colchester"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"key\n\t\t\t\t20180328154810_CIT0001","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-130-6-199903160-00016","article-title":"Assessing the generalizability of prognostic information","volume":"130","author":"Justice","year":"1999","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/sim.2987","article-title":"Comments on \u2018Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond\u2019 by M. J. Pencina","volume":"27","author":"Cook","year":"2008","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0272989X8500500203","article-title":"A visicalc program for estimating the area under a receiver operating characteristic (ROC) curve","volume":"5","author":"Centor","year":"1985","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t20180328154810_CIT0006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12170-010-0084-x","article-title":"Assessing the Incremental Role of Novel and Emerging Risk Factors","volume":"4","author":"Cook","year":"2010","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"key\n\t\t\t\t20180328154810_CIT0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/jci-2014-0007","article-title":"Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition","volume":"3","author":"Gilbert","year":"2015","journal-title":"J Causal Inference"},{"key":"key\n\t\t\t\t20180328154810_CIT0009","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10543406.2014.971174","article-title":"Statistical Validation of Surrogate Endpoints: Another Look at the Prentice Criterion and Other Criteria","volume":"25","author":"Saraf","year":"2015","journal-title":"J Biopharm Stat"},{"key":"key\n\t\t\t\t20180328154810_CIT0010","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","article-title":"Interleukin-2 therapy in patients with HIV infection","volume":"361","author":"Abrams","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0011","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000000762","article-title":"A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness","volume":"29","author":"Stein","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0012","doi-asserted-by":"crossref","first-page":"e0155100","DOI":"10.1371\/journal.pone.0155100","article-title":"Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328154810_CIT0013","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180328154810_CIT0014","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/CVI.05032-11","article-title":"Multisite comparison of high-sensitivity multiplex cytokine assays","volume":"18","author":"Breen","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20180328154810_CIT0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/CDLI.7.4.540-548.2000","article-title":"Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation","volume":"7","author":"Fahey","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20180328154810_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328154810_CIT0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","article-title":"Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals","volume":"73","author":"Herrin","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328154810_CIT0018","unstructured":"Tate JP , JusticeAC, HughesMD Performance of the refined VACS Risk Index during the first 12 months of antiretroviral therapy among US and European subjects. 15th International Workshop on HIV Observational Databases2011."},{"key":"key\n\t\t\t\t20180328154810_CIT0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/QAD.0000000000000922","article-title":"Prevalence of non-HIV cancer risk factors in persons living with HIV\/AIDS: a meta-analysis","volume":"30","author":"Park","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/apc.2006.0150","article-title":"Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men","volume":"21","author":"Floris-Moore","year":"2007","journal-title":"AIDS Patient Care STDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s","volume":"61","author":"Kelesidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0022","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/infdis\/jiw263","article-title":"Plasma Soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals","volume":"214","author":"Knudsen","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0023","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/QAI.0b013e3181685727","article-title":"Association of HIV infection and HIV\/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study","volume":"48","author":"Reingold","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328154810_CIT0024","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0b013e3283389dfa","article-title":"Inflammatory biomarkers and abacavir use in the Women\u2019s Interagency HIV Study and the Multicenter AIDS Cohort Study","volume":"24","author":"Palella","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0025","doi-asserted-by":"crossref","first-page":"e000264","DOI":"10.1161\/JAHA.113.000264","article-title":"HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation","volume":"2","author":"Baker","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20180328154810_CIT0026","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1532-5415.2006.00745.x","article-title":"Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society\/National Institute on Aging Research Conference on Frailty in Older Adults","volume":"54","author":"Walston","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20180328154810_CIT0027","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/QAD.0000000000001613","article-title":"Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults","volume":"31","author":"Tassiopoulos","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0028","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/gerona\/glt148","article-title":"Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men","volume":"69","author":"Althoff","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key\n\t\t\t\t20180328154810_CIT0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328154810_CIT0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/infdis\/jix063","article-title":"Association between frailty and components of the frailty phenotype with modifiable risk factors and antiretroviral therapy","volume":"215","author":"Erlandson","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0031","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/gerona\/glv132","article-title":"Regulatory T cells, frailty, and immune activation in men who have sex with men in the multicenter AIDS cohort study","volume":"70","author":"Zhang","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key\n\t\t\t\t20180328154810_CIT0032","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/gerona\/glt023","article-title":"Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults","volume":"69","author":"Varadhan","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key\n\t\t\t\t20180328154810_CIT0033","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/gerona\/glv107","article-title":"Frailty, inflammation, and mortality among persons aging with HIV infection and injection drug use","volume":"70","author":"Piggott","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key\n\t\t\t\t20180328154810_CIT0034","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/QAD.0b013e32835b8c7f","article-title":"An internationally generalizable risk index for mortality after one year of antiretroviral therapy","volume":"27","author":"Tate","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/QAI.0b013e31827df36c","article-title":"Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis","volume":"62","author":"Justice","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328154810_CIT0036"},{"key":"key\n\t\t\t\t20180328154810_CIT0037","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hiv.12268","article-title":"Markers of renal disease and function are associated with systemic inflammation in HIV infection","volume":"16","author":"Gupta","year":"2015","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0038","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/infdis\/jix063","article-title":"Association between frailty and components of the frailty phenotype with modifiable risk factors and antiretroviral therapy","volume":"215","author":"Erlandson","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0039","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0000000000001095","article-title":"Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation","volume":"73","author":"Mathad","year":"2016","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"key\n\t\t\t\t20180328154810_CIT0040","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/infdis\/jix113","article-title":"Immunologic pathways that predict mortality in HIV-infected Ugandans initiating antiretroviral therapy","volume":"215","author":"Lee","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0041","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180328154810_CIT0042","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","article-title":"A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus","volume":"30","author":"Thompson","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328154810_CIT0043","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jir060","article-title":"Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy","volume":"203","author":"Hunt","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0044","doi-asserted-by":"crossref","first-page":"e1005384","DOI":"10.1371\/journal.ppat.1005384","article-title":"Antibiotic and antiinflammatory therapy transiently reduces inflammation and hypercoagulation in acutely SIV-infected pigtailed macaques","volume":"12","author":"Pandrea","year":"2016","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180328154810_CIT0045","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiu515","article-title":"Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286","volume":"211","author":"Tenorio","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0046","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0047","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0048","author":"Minneapolis Medical Research Foundation"},{"key":"key\n\t\t\t\t20180328154810_CIT0049","doi-asserted-by":"crossref","first-page":"e2011030","DOI":"10.4084\/mjhid.2011.030","article-title":"HIV-associated venous thromboembolism","volume":"3","author":"Bibas","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key\n\t\t\t\t20180328154810_CIT0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1468-1293.2010.00869.x","article-title":"HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study","volume":"12","author":"Rasmussen","year":"2011","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328154810_CIT0051","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2012-03-414706","article-title":"Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates","volume":"120","author":"Pandrea","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180328154810_CIT0052","author":"NIAID"},{"key":"key\n\t\t\t\t20180328154810_CIT0053"},{"key":"key\n\t\t\t\t20180328154810_CIT0054","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/jgs.14965","article-title":"Enabling reduction of low-grade inflammation in seniors pilot study: concept, rationale, and design","volume":"65","author":"Manini","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20180328154810_CIT0055","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12):1119\u201331.","DOI":"10.1056\/NEJMoa1707914"},{"key":"key\n\t\t\t\t20180328154810_CIT0056","doi-asserted-by":"crossref","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390(10105):1833\u201342.","DOI":"10.1016\/S0140-6736(17)32247-X"},{"key":"key\n\t\t\t\t20180328154810_CIT0057","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/prca.201000073","article-title":"Taking a new biomarker into routine use\u2013a perspective from the routine clinical biochemistry laboratory","volume":"4","author":"Sturgeon","year":"2010","journal-title":"Proteomics Clin Appl"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/217\/4\/521\/24263136\/jix586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T19:39:35Z","timestamp":1603309175000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/217\/4\/521\/4641846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix586","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,15]]},"published":{"date-parts":[[2017,11,20]]}}}